Needham & Company LLC reaffirmed their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a research report released on Monday morning, Benzinga reports. The brokerage currently has a $42.00 target price on the stock.
RNAC has been the subject of a number of other research reports. Leerink Partnrs restated an outperform rating on shares of Cartesian Therapeutics in a research report on Tuesday, April 23rd. SVB Leerink assumed coverage on shares of Cartesian Therapeutics in a research report on Tuesday, April 23rd. They set an outperform rating and a $39.00 target price for the company. Mizuho assumed coverage on shares of Cartesian Therapeutics in a research report on Friday, May 24th. They set a buy rating and a $40.00 target price for the company. Oppenheimer restated an outperform rating and set a $50.00 target price on shares of Cartesian Therapeutics in a research report on Monday, June 24th. Finally, HC Wainwright restated a buy rating and set a $54.00 target price on shares of Cartesian Therapeutics in a research report on Monday, June 17th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of Buy and an average price target of $45.00.
Check Out Our Latest Stock Report on Cartesian Therapeutics
Cartesian Therapeutics Price Performance
Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($1.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.81) by ($1.16). The firm had revenue of $5.84 million for the quarter. As a group, equities analysts expect that Cartesian Therapeutics will post 2.28 EPS for the current year.
Hedge Funds Weigh In On Cartesian Therapeutics
Institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC bought a new position in Cartesian Therapeutics during the first quarter valued at $31,000. Hall Laurie J Trustee bought a new stake in shares of Cartesian Therapeutics in the 1st quarter worth about $34,000. American International Group Inc. bought a new stake in shares of Cartesian Therapeutics in the 1st quarter worth about $37,000. BNP Paribas Financial Markets bought a new stake in shares of Cartesian Therapeutics in the 1st quarter worth about $38,000. Finally, Delphi Financial Group Inc. bought a new stake in shares of Cartesian Therapeutics in the 1st quarter worth about $430,000. Institutional investors own 86.95% of the company’s stock.
Cartesian Therapeutics Company Profile
Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.
Featured Stories
- Five stocks we like better than Cartesian Therapeutics
- Compound Interest and Why It Matters When Investing
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Consumer Discretionary Stocks Explained
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.